Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial
Authors' conclusion
Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.
Study context
- Population
- Patients with a recent (≤14 days) myocardial infarction (MI) and left ventricular ejection fraction (LVEF) >40%randomised, 2681 (99%) completed at least one EQ-5D-5L questionnaire
- Participants
- 2,707 patients
- Comparison
- Beta-blocker therapy or no beta-blocker
- Primary endpoint
- Between-group differences in change from baseline in EQ-5D index score and EQ VAS score
- Follow-up
- 12 months
Methodological detailsrandomised, open-label
- Randomised
- Open-label
Primary result
As reported in the abstract
beta-blocker vs no beta-blockerMean difference (95% CI)P value
EQ-5D index score
−0.001(−0.016 to 0.013)
P = 0.86EQ VAS score
−1.35(−2.85 to 0.15)
P = 0.08Further findings
Baseline EQ-5D and EQ VAS scores
- Median EQ-5D score
- 0.95 (IQR: 0.87-1.00)
- Median EQ VAS score
- 77 (IQR: 65-87)
- Scores remained stable throughout follow-up
Prespecified subgroups (age, sex, type of MI, and LVEF)
- Results were consistent in prespecified subgroups
Original publication
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial. Eur Heart J Cardiovasc Pharmacother. Published 11 November 2026. doi:10. 1093/ ehjcvp/ pvag096
Composed by AI from the published abstract and checked against it. How Briefs are made →